Abstract
In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.
Original language | English (US) |
---|---|
Pages (from-to) | 1-9 |
Number of pages | 9 |
Journal | Journal of Clinical Immunology |
Volume | 20 |
Issue number | 1 |
DOIs | |
State | Published - 2000 |
Keywords
- Autoimmune disease
- Gene-marked autologous stem cells
- Hematopoietic stem cell transplantation
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology